| Doxorubicin | Etoposide | Paclitaxel | Vincristine | Carboplatin |
---|
IMR-32
| (nM) | (nM) | (nM) | (nM) | (nM) |
LY379196 |
A
|
B
|
A
|
B
|
A
|
B
|
A
|
B
|
A
|
B
|
0 nM | 6.3 | | 110 | | 1.7 | | 0.51 | | 760 | |
20 nM | 5.5 | 5.3 | 101 | 118 | 1.6 | 1.7 | 0.47 | 0.57 | 780 | 740 |
100 nM | 5.5 | 4.7 | 88 | 98 | 1.4 | 1.6 | 0.40 | 0.47 | 880 | 720 |
500 nM | 6.1 | 2.8 | 103 | 78 | 1.6 | 1.0 | 0.37 | 0.30 | 880 | 380 |
SH-SY5Y
| (nM) | (nM) | (nM) | (nM) | (μM) |
LY379196 |
A
|
B
|
A
|
B
|
A
|
B
|
A
|
B
|
A
|
B
|
0 nM | 9.3 | | 109 | | 8.3 | | 1.41 | | 1.9 | |
20 nM | 8.2 | 9.8 | 93 | 114 | 7.3 | 8.0 | 1.20 | 1.45 | 2.2 | 2.3 |
100 nM | 7.2 | 6.7 | 74 | 81 | 4.8 | 4.3 | 0.82 | 0.89 | 2.1 | 1.8 |
500 nM | 5.0 | 2.0 | 75 | 55 | 4.3 | 2.7 | 0.57 | 0.33 | 2.0 | 0.7 |
SK-N-BE(2)
| (nM) | (μM) | (nM) | (nM) | (μM) |
LY379196 |
A
|
B
|
A
|
B
|
A
|
B
|
A
|
B
|
A
|
B
|
0 nM | 920 | | 7.2 | | 117 | | 42 | | >100 | |
20 nM | 650 | 690 | 6.4 | 6.6 | 108 | 109 | 32 | 33 | >100 | >100 |
100 nM | 450 | 380 | 5.3 | 4.8 | 105 | 94 | 21 | 21 | >100 | >100 |
500 nM | 270 | 160 | 3.9 | 2.8 | 40 | 27 | 5.2 | 3.9 | >100 | >100 |
- This table shows the concentrations (ED50) of the chemotherapeutic drugs, in the presence of different LY379196 concentrations, needed to suppress the number of viable cells after three (SK-N-BE(2)) or four (IMR-32 and SH-SY5Y) days in culture to 50% of the amount obtained in the absence of the drug. The data used for calculations are obtained from Figure 2. Values are geometric mean of three separate experiments with triplicate measurements. The ED50 values were calculated using the amount of viable cells in the absence of chemotherapeutic drug but in the presence of LY379196 as 100% (values in A columns) or the amount of viable cells in the absence of anticancer drug and LY379196 (values in B columns). Thus, values in column A reflect the potency of the chemotherapeutic drug since the inherent growth-suppressing effect of LY379196 has been eliminated in the calculations, whereas values in column B reflect the combined growth-suppressing effect of LY379196 and chemotherapeutic drug. For carboplatin treatment of SK-N-BE(2) cells a reduction in viable cell amount by 50% was not obtained within the concentration range used.